Boardroom Alpha
10-K primary document
ONC · Annual Report (Form 10-K) · Filed February 26, 2026

Beone Medicines Ltd10-K exhibit

exhibit21-2025q4beonemedic.htm
Document
Exhibit 21
Subsidiaries
Name of SubsidiaryJurisdiction of Incorporation or OrganizationPercentage of Ownership by the Registrant
BeiGene 101Cayman Islands100 %
BeOne Medicines Argentina S.R.LArgentina100 %
BeOne Medicines AUS PTY LTDAustralia100 %
BeOne Medicines Austria GmbHAustria100 %
BeOne Medicines (Beijing) Co., Ltd.People’s Republic of China100 %
BeOne Medicines Belgium SRLBelgium100 %
BeOne Biologics Co., Ltd.People’s Republic of China100 %
BeOne Medicines Brasil Ltda.Brazil100 %
BeOne Medicines (Canada) ULCCanada100 %
BeOne Medicines Chile LimitadaChile100 %
BeOne Medicines Colombia S.A.S.Colombia100 %
BeOne Medicines ESP, S.L.U. (Spain)Spain100 %
BeOne Medicines France SarlFrance100 %
BeOne Medicines Germany GmbHGermany100 %
BeOne Guangzhou Biologics Manufacturing Co., Ltd.People’s Republic of China100 %
BeOne (Guangzhou) Innovation Technology Co., Ltd.People’s Republic of China100 %
BeOne Medicines (Hong Kong) Co., LimitedHong Kong100 %
BeOne Medicines Hopewell Urban Renewal, LLCNew Jersey, United States100 %
BeOne Medicines International GmbHSwitzerland100 %
BeOne Medicines Ireland LimitedRepublic of Ireland100 %
BeOne Medicines Italy S.r.l.Italy100 %
BeOne Medicines JapanJapan100 %
BeOne Medicines Korea Y.H.South Korea100 %
BeOne Medicines Malaysia Sdn Bhd.Malaysia100 %
BeOne Medicines Mexico S. de R.L. de C.V.Mexico100 %
BeOne Medicines Netherlands B.V.Netherlands100 %
BeOne Medicines NZ UnlimitedNew Zealand100 %
BeOne Medicines Peru (Sociedad Comercial de Responsabilidad Limitada - S.R.L)Peru100 %
BeOne Medicines Pharmaceuticals GmbHSwitzerland100 %
BeOne Pharmaceutical (Guangzhou) Co., Ltd.People’s Republic of China100 %
BeOne Medicines Israel Ltd. Israel100 %
BeOne Pharmaceutical (Shanghai) Co., Ltd.People’s Republic of China100 %
BeOne Medicines Poland sp. z o.o.Poland100 %
BeOne Medicines Portugal, Unipessoal LdaPortugal100 %
BeiGene ShanghaiCayman Islands100 %
BeiGene Shanghai 101Cayman Islands100 %
BeOne Medicines (Shanghai) Co., Ltd.People’s Republic of China100 %
BeOne Medicines (Shanghai) Development Co., Ltd. People’s Republic of China100 %
BeOne Medicines (Shanghai) Management Consulting Co., Ltd.People’s Republic of China100 %
BeOne Medicines (Shanghai) Research & Development Co., Ltd.People’s Republic of China100 %
BeOne Medicines Shanghai Asset LimitedHong Kong100 %
BeOne Medicines Singapore Pte. LtdSingapore100 %
BeOne Medicines South Africa (PTY) Ltd. South Africa100 %
BeOne Pharmaceutical (Suzhou) Co., Ltd.People’s Republic of China100 %


Exhibit 21
BeOne Medicines Sweden ABSweden100 %
BeOne Medicines (Taiwan) LimitedTaiwan100 %
BeiGene (Thailand) Ltd. Thailand100 %
BeiGene Turkey Medical Products Trade Limited CompanyTurkey100 %
BeOne Medicines UK, Ltd.United Kingdom100 %
BeOne Medicines United Kingdom, Ltd.United Kingdom100 %
BeOne Medicines USA, Inc.Delaware, United States100 %
BeOne Medicines US Holdings, LLCDelaware, United States100 %
BeOne Medicines US Manufacturing Co., Inc.Delaware, United States100 %
Beijing Innerway Bio-tech Co., Ltd.People’s Republic of China100 %
BeOne Medicines Global Business Services Sp. Z o.o.Poland100 %
BG NC 1, Ltd. Cayman Islands100 %
BG NC 2, Ltd. Cayman Islands100 %
Newco 101Cayman Islands100 %
SuGene Pharmaceuticals (Suzhou) Co., Ltd. People’s Republic of China100 %
BeOne Medicines Treasury Ltd.Cayman Islands100 %
BeOne Medicines I GmbHSwitzerland100 %
BeOne Medicines d.o.o. BeogradSerbia100 %


Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer